EUCTR2009-013407-66-IT进行中（未招募）不适用
A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject must have received tivozanib while enrolled in another protocol, must be tolerating study drug and must currently display clinical benefit. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the parent protocol (AV-951-12-205). 2. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment. 3. Ability to give written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 96
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 64
排除标准
- •1. > 4 weeks since discontinuation of tivozanib treatment on a previous protocol 2. If female, pregnant or lactating 3. Sexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Highly effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.) 4. Uncontrolled hypertension: systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart. 5. Newly identified CNS malignancies or documented progression of CNS metastases; subjects will be allowed only if the CNS metastases have been adequately treated with radiotherapy or surgery. For subjects receiving steroid therapy please refer to Section 6.3 for allowed steroid maintenance therapy. 6. Unhealed wounds (including active peptic ulcers) 7. Serious/active infection or infection requiring parenteral antibiotics 8. Life-threatening illness or organ system dysfunction compromising safety evaluation 9. Psychiatric disorder, altered mental status precluding informed consent or necessary testing 10. Inability to comply with protocol requirements
研究者
相似试验
进行中（未招募）
不适用
Study to continue giving Tivozanib to subjects participating in other studies with TivozanibRenal Cell CarcinomaMedDRA version: 16.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-013407-66-PLAVEO Pharmaceuticals, Inc.82
进行中（未招募）
不适用
Study to continue giving Tivozanib to subject participating in other studies with TivozanibEUCTR2009-013407-66-HUAVEO Pharmaceuticals, Inc.82
进行中（未招募）
不适用
Study to continue giving Tivozanib to subject participating in other studies with TivozanibRenal Cell CarcinomaEUCTR2009-013407-66-BGAVEO Pharmaceuticals, Inc.82
进行中（未招募）
不适用
Study to continue giving Tivozanib hydrochloride to subjects participating in other studies with Tivozanib hydrochlorideEUCTR2009-013407-66-GBAVEO Pharmaceuticals, Inc.
进行中（未招募）
1 期
Study to continue giving Tivozanib to subject participating in other studies with TivozanibRenal Cell Carcinoma Stage III, Renal Cell Carcinoma Stage IV, Metastatic Renal Cell Carcinoma,MedDRA version: 16.1Level: LLTClassification code 10038400Term: Renal carcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10038399Term: Renal carcinoma stage IIISystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2009-013407-66-BEAVEO Pharmaceuticals, Inc.